(Q33889276)

29 July 2017

title

Management of Hormone-Sensitive and Hormone-Refractory Metastatic Prostate Cancer (English)

1 reference

29 July 2017

1 reference

Rago R

1

1 reference

29 July 2017

publication date

1 November 1998

1 reference

29 July 2017

1 reference

29 July 2017

volume

5

1 reference

29 July 2017

issue

6

1 reference

29 July 2017

page(s)

513-521

1 reference

29 July 2017

cites work

Cancer statistics, 1998.

1 reference

https://api.crossref.org/works/10.1177%2F107327489800500604

A controlled trial of leuprolide with and without flutamide in prostatic carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327489800500604

Proceedings: The Veterans Administration Cooperative Urological Research Group's studies of cancer of the prostate

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327489800500604

Patients' choice of treatment in stage D prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327489800500604

Intermittent androgen deprivation after PSA-complete response as a strategy to reduce induction of hormone-resistant prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327489800500604

Maximum androgen blockade in advanced prostate cancer: a meta-analysis of published randomized controlled trials using nonsteroidal antiandrogens

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327489800500604

Long-term efficacy and safety of nilutamide plus castration in advanced prostate cancer, and the significance of early prostate specific antigen normalization. International Anandron Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327489800500604

Maximal androgen blockade: final analysis of EORTC phase III trial 30853. EORTC Genito-Urinary Tract Cancer Cooperative Group and the EORTC Data Center

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327489800500604

Carcinoma of the prostate: treatment with external radiotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327489800500604

Extended experience with surgical treatment of stage D1 adenocarcinoma of prostate. Significant influences of immediate adjuvant hormonal treatment (orchiectomy) on outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327489800500604

Prognosis of patients with stage D1 prostate carcinoma following radical prostatectomy with and without early endocrine therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327489800500604

Immediate versus deferred treatment for advanced prostatic cancer: initial results of the Medical Research Council trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327489800500604

A mutation in the ligand binding domain of the androgen receptor of human LNCaP cells affects steroid binding characteristics and response to anti-androgens

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327489800500604

The antiandrogen withdrawal syndrome. Experience in a large cohort of unselected patients with advanced prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327489800500604

Flutamide withdrawal syndrome: its impact on clinical trials in hormone-refractory prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327489800500604

Hormone and antihormone withdrawal: implications for the management of androgen-independent prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327489800500604

Surprising activity of flutamide withdrawal, when combined with aminoglutethimide, in treatment of "hormone-refractory" prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327489800500604

Treatment of metastatic prostatic cancer with low-dose prednisone: evaluation of pain and quality of life as pragmatic indices of response

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327489800500604

Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327489800500604

10.1177/107327489800500604

21 January 2018

Identifiers

DOI

0 references

1 reference